{"title":"Endocrine \/ GH","description":"","products":[{"product_id":"tesamorelin","title":"Tesamorelin","description":"\u003cdiv class=\"prod-section\"\u003e\n    \u003cdiv class=\"prod-section-label\"\u003e\n        \u003ci class=\"ti ti-file-description\"\u003e\u003c\/i\u003eResearch Background\n    \u003c\/div\u003e\n\n    \u003cp class=\"prod-para\"\u003e\n        Tesamorelin (CAS 901758-09-6; MW 5195.9 g\/mol; C223H370N72O69S) is a synthetic 44-amino acid analog of endogenous Growth Hormone-Releasing Hormone (GHRH) engineered with a trans-3-hexanoic acid modification at the N-terminus. This structural modification preserves full GHRH receptor binding affinity while dramatically enhancing resistance to dipeptidyl peptidase-IV (DPP-IV) enzymatic cleavage, extending the compound's activity window compared to unmodified native GHRH.\n    \u003c\/p\u003e\n\n    \u003cp class=\"prod-para\"\u003e\n        Tesamorelin is the only FDA-approved GHRH analog — approved as Egrifta for treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. This distinction makes it one of the most rigorously characterized peptides available to research researchers, supported by multiple large Phase III clinical trials involving over 800 patients.\n    \u003c\/p\u003e\n\n    \u003cp class=\"prod-para\"\u003e\n        Mechanistically, tesamorelin binds and activates the GHRH receptor in the anterior pituitary — a class B GPCR signaling via Gs\/adenylate cyclase\/cAMP\/PKA cascades. Receptor engagement stimulates somatotroph cells to synthesize and release endogenous growth hormone (GH), which drives hepatic production of Insulin-like Growth Factor-1 (IGF-1). Clinical data show average IGF-1 elevations of approximately 181 ug\/L in men. Unlike exogenous GH administration, tesamorelin preserves natural pituitary feedback loops — maintaining the body's own negative-feedback mechanisms, an important experimental control variable in GH axis research.\n    \u003c\/p\u003e\n\n    \u003cp class=\"prod-para\"\u003e\n        Beyond visceral adipose tissue (VAT) reduction, clinical studies have documented reductions in carotid intima-media thickness (cIMT), C-reactive protein (CRP), and triglycerides. Emerging data indicate potential cognitive benefits — improved executive function and memory in healthy older adults.\n    \u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv class=\"prod-section\"\u003e\n    \u003cdiv class=\"prod-section-label\"\u003e\n        \u003ci class=\"ti ti-atom\"\u003e\u003c\/i\u003ePhysicochemical Data\n    \u003c\/div\u003e\n\n    \u003cdiv class=\"table-scroll\"\u003e\n        \u003ctable class=\"prod-table\"\u003e\n            \u003cthead\u003e\n                \u003ctr\u003e\n                    \u003cth\u003eCompound\u003c\/th\u003e\n                    \u003cth\u003eFormula\u003c\/th\u003e\n                    \u003cth\u003eMW\u003c\/th\u003e\n                    \u003cth\u003eCAS No.\u003c\/th\u003e\n                    \u003cth\u003eSequence \/ Structure\u003c\/th\u003e\n                    \u003cth\u003eReceptor \/ Target\u003c\/th\u003e\n                \u003c\/tr\u003e\n            \u003c\/thead\u003e\n\n            \u003ctbody\u003e\n                \u003ctr class=\"row-alt\"\u003e\n                    \u003ctd class=\"td-bold\"\u003eTesamorelin\u003c\/td\u003e\n                    \u003ctd\u003eC223H370N72O69S\u003c\/td\u003e\n                    \u003ctd\u003e5195.9 g\/mol\u003c\/td\u003e\n                    \u003ctd\u003e901758-09-6\u003c\/td\u003e\n                    \u003ctd\u003e44-AA GHRH analog; trans-3-hexanoic acid N-terminal modification\u003c\/td\u003e\n                    \u003ctd\u003eGHRH receptor agonist (Gs\/cAMP\/PKA); anterior pituitary GH secretagogue\u003c\/td\u003e\n                \u003c\/tr\u003e\n            \u003c\/tbody\u003e\n        \u003c\/table\u003e\n    \u003c\/div\u003e\n\u003c\/div\u003e","brand":"General Peptide","offers":[{"title":"1 Vial","offer_id":50856763064567,"sku":null,"price":91.0,"currency_code":"USD","in_stock":true},{"title":"3 Vials","offer_id":50856763097335,"sku":null,"price":246.0,"currency_code":"USD","in_stock":true},{"title":"5 Vials","offer_id":50856763130103,"sku":null,"price":364.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0934\/1485\/0807\/files\/Endocrine-GH_Tesamorelin.jpg?v=1781173935"},{"product_id":"cjc-1295-no-dac","title":"CJC-1295 (No DAC)","description":"\u003cdiv class=\"prod-section\"\u003e \u003cdiv class=\"prod-section-label\"\u003e \u003ci class=\"ti ti-file-description\"\u003e\u003c\/i\u003eResearch Background \u003c\/div\u003e \u003cp class=\"prod-para\"\u003e CJC-1295 (No DAC) is a modified GRF(1-29), a 29-amino acid GHRH analog with four amino acid substitutions that enhance alpha-helical structure and confer 49x greater receptor potency versus native GHRH. The No DAC version features a shorter in vivo half-life (~30 minutes) designed for discrete pulsatile GH signal research, allowing researchers to study physiological growth hormone release patterns without the extended release profile of the DAC-modified version. \u003c\/p\u003e \u003cp class=\"prod-para\"\u003e CJC-1295 functions as a potent GHRH receptor agonist, binding to and activating growth hormone-releasing hormone receptors on pituitary somatotroph cells. The four amino acid substitutions (Aib, Gln, Ala, and Leu at positions 2, 8, 15, and 27) protect against enzymatic degradation while maintaining receptor binding affinity. This structural modification results in significantly enhanced stability and bioavailability compared to unmodified GRF(1-29). \u003c\/p\u003e \u003cp class=\"prod-para\"\u003e In research applications, CJC-1295 (No DAC) stimulates pulsatile growth hormone release, leading to increased IGF-1 production in hepatic and peripheral tissues. The absence of the Drug Affinity Complex (DAC) means the peptide does not bind to albumin for extended circulation, resulting in a more physiological release pattern that mimics natural GH pulsatility. This makes it particularly valuable for research protocols requiring precise temporal control over GH signaling. \u003c\/p\u003e \u003cp class=\"prod-para\"\u003e The peptide demonstrates remarkable efficacy in stimulating GH release without significantly affecting cortisol, prolactin, or other stress hormone levels when used appropriately. This selectivity makes it a preferred research tool for studying GH axis function, anabolic processes, metabolic regulation, and age-related endocrine changes without confounding effects from other hormonal systems. \u003c\/p\u003e \u003c\/div\u003e \u003cdiv class=\"prod-section\"\u003e \u003cdiv class=\"prod-section-label\"\u003e \u003ci class=\"ti ti-atom\"\u003e\u003c\/i\u003ePhysicochemical Data \u003c\/div\u003e \u003cdiv class=\"table-scroll\"\u003e \u003ctable class=\"prod-table\"\u003e \u003cthead\u003e \u003ctr\u003e \u003cth\u003eCompound\u003c\/th\u003e \u003cth\u003eMW \/ Formula\u003c\/th\u003e \u003cth\u003eCAS No.\u003c\/th\u003e \u003cth\u003eSequence \/ Structure\u003c\/th\u003e \u003cth\u003eReceptor \/ Target\u003c\/th\u003e \u003c\/tr\u003e \u003c\/thead\u003e \u003ctbody\u003e \u003ctr class=\"row-alt\"\u003e \u003ctd class=\"td-bold\"\u003eCJC-1295 (No DAC)\u003c\/td\u003e \u003ctd\u003e~3367 g\/mol\u003c\/td\u003e \u003ctd\u003e863288-34-0\u003c\/td\u003e \u003ctd\u003e29-AA GHRH fragment; 4× substitutions; 49× native GHRH potency\u003c\/td\u003e \u003ctd\u003eModified GRF(1-29); GHRH receptor agonist\u003c\/td\u003e \u003c\/tr\u003e \u003c\/tbody\u003e \u003c\/table\u003e \u003c\/div\u003e \u003c\/div\u003e","brand":"General Peptide","offers":[{"title":"1 Vial","offer_id":50856778137847,"sku":null,"price":47.0,"currency_code":"USD","in_stock":true},{"title":"3 Vials","offer_id":50856778170615,"sku":null,"price":127.0,"currency_code":"USD","in_stock":true},{"title":"5 Vials","offer_id":50856778203383,"sku":null,"price":188.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0934\/1485\/0807\/files\/Endocrine-GH_CJC-1295-_No-DAC.jpg?v=1781176582"},{"product_id":"ipamorelin-1","title":"Ipamorelin","description":"\u003cdiv class=\"prod-section\"\u003e \u003cdiv class=\"prod-section-label\"\u003e \u003ci class=\"ti ti-file-description\"\u003e\u003c\/i\u003eResearch Background \u003c\/div\u003e \u003cp class=\"prod-para\"\u003e Ipamorelin is a selective pentapeptide GHS-R1a (ghrelin receptor) agonist (CAS 170851-70-4; MW 711.9 g\/mol) that functions through Ca2+\/IP3 signaling pathways. It represents the most selective growth hormone-releasing peptide (GHRP) available for clean GH secretagogue research, as it does not stimulate ACTH, cortisol, or prolactin at research concentrations. \u003c\/p\u003e \u003cp class=\"prod-para\"\u003e As a fifth-generation GHRP, Ipamorelin demonstrates exceptional receptor selectivity, binding specifically to the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells without off-target effects on other hormonal axes. This selectivity profile distinguishes it from earlier-generation GHRPs that often caused unwanted elevations in cortisol, prolactin, or ACTH, making Ipamorelin the preferred research tool for isolating GH-specific effects. \u003c\/p\u003e \u003cp class=\"prod-para\"\u003e The pentapeptide structure (Aib-His-D-2-Me-Trp-Phe-Lys-NH2) mimics the endogenous ghrelin hormone while providing enhanced metabolic stability and receptor binding affinity. Upon binding to GHS-R1a, Ipamorelin triggers intracellular calcium release and inositol trisphosphate (IP3) signaling, resulting in pulsatile growth hormone release from pituitary stores. \u003c\/p\u003e \u003cp class=\"prod-para\"\u003e In research applications, Ipamorelin demonstrates synergistic effects when combined with GHRH analogs like CJC-1295, as they activate complementary pathways — GHRH increases cAMP while GHS-R1a agonists increase intracellular calcium, together producing supra-additive GH release. This makes it particularly valuable for studies examining GH axis function, body composition, metabolic regulation, and age-related endocrine changes. \u003c\/p\u003e \u003c\/div\u003e \u003cdiv class=\"prod-section\"\u003e \u003cdiv class=\"prod-section-label\"\u003e \u003ci class=\"ti ti-atom\"\u003e\u003c\/i\u003ePhysicochemical Data \u003c\/div\u003e \u003cdiv class=\"table-scroll\"\u003e \u003ctable class=\"prod-table\"\u003e \u003cthead\u003e \u003ctr\u003e \u003cth\u003eCompound\u003c\/th\u003e \u003cth\u003eMW \/ Formula\u003c\/th\u003e \u003cth\u003eCAS No.\u003c\/th\u003e \u003cth\u003eSequence \/ Structure\u003c\/th\u003e \u003cth\u003eReceptor \/ Target\u003c\/th\u003e \u003c\/tr\u003e \u003c\/thead\u003e \u003ctbody\u003e \u003ctr class=\"row-alt\"\u003e \u003ctd class=\"td-bold\"\u003eIpamorelin\u003c\/td\u003e \u003ctd\u003eC38H49N9O5 \/ 711.9 g\/mol\u003c\/td\u003e \u003ctd\u003e170851-70-4\u003c\/td\u003e \u003ctd\u003ePentapeptide ghrelin mimetic\u003c\/td\u003e \u003ctd\u003eGHS-R1a agonist; no ACTH\/cortisol stimulation\u003c\/td\u003e \u003c\/tr\u003e \u003c\/tbody\u003e \u003c\/table\u003e \u003c\/div\u003e \u003c\/div\u003e","brand":"General Peptide","offers":[{"title":"1 Vial","offer_id":50856778793207,"sku":null,"price":24.0,"currency_code":"USD","in_stock":true},{"title":"3 Vials","offer_id":50856778825975,"sku":null,"price":65.0,"currency_code":"USD","in_stock":true},{"title":"5 Vials","offer_id":50856778858743,"sku":null,"price":96.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0934\/1485\/0807\/files\/Endocrine-GH_Ipamorelin.jpg?v=1781176997"},{"product_id":"ace-031","title":"ACE-031","description":"\u003cdiv class=\"prod-section\"\u003e\n\u003cdiv class=\"prod-section-label\"\u003e\n\u003ci class=\"ti ti-file-description\"\u003e\u003c\/i\u003eResearch Background\u003c\/div\u003e\n\u003cp class=\"prod-para\"\u003eACE-031 (ActRIIB-Fc) is a soluble fusion protein comprising the extracellular domain of Activin Receptor Type IIB (ActRIIB) linked to the Fc region of human IgG1. It functions as a decoy receptor that binds and sequesters myostatin (GDF-8), activin A, and related members of the TGF-beta superfamily that normally act to limit skeletal muscle growth. By neutralizing these endogenous inhibitory ligands, ACE-031 has become a valuable research tool for investigating myogenesis, muscle maintenance, and regenerative biology.\u003c\/p\u003e\n\u003cp class=\"prod-para\"\u003eThis glycoprotein fusion construct (MW approximately 90 kDa) operates through a ligand-trap mechanism, preventing myostatin and associated growth differentiation factors from interacting with their native cell-surface receptors. Under physiological conditions, myostatin regulates muscle homeostasis by activating Smad2\/3 signaling pathways, thereby restricting muscle growth. Sequestration of circulating myostatin by ACE-031 effectively removes this inhibitory checkpoint, allowing enhanced investigation of muscle development and repair processes.\u003c\/p\u003e\n\u003cp class=\"prod-para\"\u003eIn research settings, ACE-031 has been evaluated in models of Duchenne muscular dystrophy, cachexia, and other muscle-wasting conditions, including studies referenced under ClinicalTrials.gov Identifier: NCT00952887. Experimental findings have demonstrated increases in muscle mass, improvements in muscle performance, and enhanced regenerative capacity across various preclinical systems. Unlike direct anabolic agents, ACE-031 complements growth-promoting stimuli by suppressing inhibitory signaling rather than actively stimulating anabolic pathways.\u003c\/p\u003e\n\u003cp class=\"prod-para\"\u003eThe ligand-binding profile of ACE-031 extends beyond myostatin to include activin A, GDF-11, and additional TGF-beta superfamily ligands. This broader activity makes it particularly useful for examining the interconnected signaling networks involved in regulating muscle mass, bone remodeling, tissue regeneration, and catabolic control. Its ability to simultaneously neutralize multiple inhibitory factors provides a comprehensive approach for studying pathways governing musculoskeletal adaptation.\u003c\/p\u003e\n\u003cdiv class=\"prod-table-wrap\"\u003e\n\u003ctable class=\"prod-table\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCompound\u003c\/th\u003e\n\u003cth\u003eMW \/ Formula\u003c\/th\u003e\n\u003cth\u003eCAS No.\u003c\/th\u003e\n\u003cth\u003eSequence \/ Structure\u003c\/th\u003e\n\u003cth\u003eReceptor \/ Target\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eACE-031 (ActRIIB-Fc)\u003c\/td\u003e\n\u003ctd\u003e~90 kDa (glycoprotein)\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eSoluble ActRIIB extracellular domain fused to human IgG1 Fc\u003c\/td\u003e\n\u003ctd\u003eMyostatin\/activin decoy receptor; TGF-beta superfamily ligand trap\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cp class=\"prod-note\"\u003e \u003c\/p\u003e\n\u003c\/div\u003e","brand":"General Peptide","offers":[{"title":"1 Vial","offer_id":50856846393591,"sku":null,"price":174.0,"currency_code":"USD","in_stock":true},{"title":"3 Vials","offer_id":50856846426359,"sku":null,"price":470.0,"currency_code":"USD","in_stock":true},{"title":"5 Vials","offer_id":50856846459127,"sku":null,"price":696.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0934\/1485\/0807\/files\/Receptor-Biology_ACE-031.jpg?v=1781182215"}],"url":"https:\/\/generalpeptide.com\/collections\/endocrine-gh.oembed","provider":"General Peptide","version":"1.0","type":"link"}